Persistent C-peptide levels and microvascular complications in childhood onset type 1 diabetes of long duration

被引:13
|
作者
Williams, Katherine V. [1 ]
Becker, Dorothy J. [2 ]
Orchard, Trevor J. [1 ]
Costacou, Tina [1 ]
机构
[1] Univ Pittsburgh, Dept Epidemiol, DLR Bldg,3512 Fifth Ave, Pittsburgh, PA 15213 USA
[2] Childrens Hosp Pittsburgh, Div Endocrinol, 4401 Penn Ave, Pittsburgh, PA 15224 USA
基金
美国国家卫生研究院;
关键词
Type; 1; diabetes; C-peptide; Microvascular complications; Diabetic retinopathy; Macroalbuminuria; Diabetic nephropathy; PITTSBURGH EPIDEMIOLOGY; PREVALENCE; RISK; IDDM;
D O I
10.1016/j.jdiacomp.2019.05.019
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: The aim was to determine if persistent c-peptide in long duration childhood onset (<17 years) type 1 diabetes (T1D) related to microvascular complications. Methods: Pittsburgh Epidemiology of Diabetes Complications (EDC) participants (n = 185) had serum c-peptide levels measured by Mercodia ultra-sensitive ELISA at the 25-year follow-up exam. Microvascular complications between those with and without detectable c-peptide were compared. Results: Eighteen (9.7%) participants had detectable median c-peptide levels of 3.8 (2.6, 12.2) pmol/L and did not differ from those without detectable levels. No differences in microalbuminuria, confirmed distal symmetric polyneuropathy, renal failure, or between those with one or more complications were found between the two groups. Proliferative retinopathy (PR) was marginally lower in those with detectable c-peptide (33.3% vs 55.1%, p = 0.08). However, those with c-peptide were somewhat less likely to have fasted for a full 8-h (66.7% vs. 84.9%, p = 0.09). Excluding those not fully fasted, PR no longer approached significance but macroalbuminuria became marginally lower in those with detectable levels (23.4% vs 0%, p = 0.07). Conclusions: Low levels of c-peptide in T1D patients of long duration were detected but were not strongly related to microvascular complications. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页码:657 / 661
页数:5
相关论文
共 50 条
  • [31] C-peptide an adequate endpoint in type 1 diabetes
    Ludvigsson, Johnny
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2009, 25 (08) : 691 - 693
  • [32] An Association of Fasting C-Peptide Levels and Vascular Complications in Chronic Type 2 Diabetes Mellitus Patients
    Thippeswamy, T.
    Nithin, Nirmal
    Chikkegowda, Prathima
    JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2021, 15 (02) : OC10 - OC13
  • [33] C-peptide in the natural history of type 1 diabetes
    Palmer, Jerry P.
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2009, 25 (04) : 325 - 328
  • [34] Genetics of serum C-peptide in type 1 diabetes
    Paterson, A. D.
    Roshandel, D.
    Spiliopoulou, A.
    McGurnaghan, S.
    Bull, S. B.
    McKeigue, P. M.
    Colhoun, H. M.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S36 - S36
  • [35] C-Peptide as a Therapy for Type 1 Diabetes Mellitus
    Washburn, Rachel L.
    Mueller, Karl
    Kaur, Gurvinder
    Moreno, Tanir
    Moustaid-Moussa, Naima
    Ramalingam, Latha
    Dufour, Jannette M.
    BIOMEDICINES, 2021, 9 (03) : 1 - 24
  • [36] Distinct diagnostic criteria of fulminant type 1 diabetes based on serum C-peptide response and HbA1c levels at onset
    Tanaka, S
    Endo, T
    Aida, K
    Shimura, H
    Yokomori, N
    Kaneshige, M
    Furuya, F
    Amemiya, S
    Mochizuki, M
    Nakanishi, K
    Kobayashi, T
    DIABETES CARE, 2004, 27 (08) : 1936 - 1941
  • [37] Clinical Impact of Residual C-Peptide Secretion in Type 1 Diabetes on Glycemia and Microvascular Complications (vol 44, pg 390, 2021)
    Jeyam, Anita
    Colhoun, Helen
    McGurnaghan, Stuart
    Blackbourn, Luke
    McDonald, Timothy J.
    Palmer, Colin N. A.
    McKnight, John A.
    Strachan, Mark W. J.
    Patrick, Alan W.
    Chalmers, John
    Lindsay, Robert S.
    Petrie, John R.
    Thekkepat, Sandeep
    Collier, Andrew
    MacRury, Sandra
    McKeigue, Paul M.
    DIABETES CARE, 2021, 44 (04) : 1072 - 1072
  • [38] C-peptide and HbA1c levels at diagnosis indicate a different pathogenic process depending on the age at onset of Type 1 diabetes
    Pozzilli, P
    Pitocco, D
    Visalli, N
    Spera, S
    Corbi, S
    Suraci, C
    Crinò, A
    Patera, P
    Matteoli, MC
    Costanza, F
    Fioriti, E
    Ghirlanda, G
    Cappa, M
    DIABETOLOGIA, 2004, 47 : A299 - A299
  • [39] C-peptide and HbA1c levels at diagnosis indicate a different pathogenic process depending on the age of onset of type 1 diabetes
    Pozzilli, P
    Visalli, N
    Picardi, A
    Manfrini, S
    Crino, A
    Suraci, C
    Pitocco, D
    Ghirlanda, G
    Patera, P
    DIABETES, 2004, 53 : A603 - A603
  • [40] Low levels of C-peptide production protect from complications and improve HbA1c control in longstanding type 1 diabetes
    Faustman, D. L.
    Reinhold, P. E.
    Washer, S. L.
    Hsu, E.
    Zhao, M.
    Burger, D.
    Zheng, H.
    DIABETOLOGIA, 2014, 57 : S45 - S45